The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure

No abstract is available for this paper.

• Publication year

  2015

• Venue

  JBIC Journal of Biological Inorganic Chemistry

• Publication date

  2015-05-16

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00775-015-1269-zPMID 25982099
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

  2015cited by this paper
• Preclinical combination therapy of the investigational drug NAMI-A+ with doxorubicin for mammary cancer

  2015cited by this paper
• NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels.

  2014cited by this paper
• Targetting cancer with Ru(III/II)-phosphodiesterase inhibitor adducts: a novel approach in the treatment of cancer.

  2013cited by this paper
• Features and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice.

  2013cited by this paper
• CDK1 hyperphosphorylation maintenance drives the time-course of G2-M cell cycle arrest after short treatment with NAMI-A in Kb cells.

  2012cited by this paper
• Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs.

  2012cited by this paper
• Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.

  2011cited by this paper
• Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

  2010cited by this paper
• Guidelines for the welfare and use of animals in cancer research

  2010cited by this paper
• Recent developments in ruthenium anticancer drugs.

  2009cited by this paper
• Doxorubicin Cardiomyopathy

  2009cited by this paper
• Ruthenium complexes as anticancer agents.

  2006cited by this paper
• DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.

  2006cited by this paper
• The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy.

  2006cited by this paper
• A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

  2004cited by this paper
• Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.

  2003cited by this paper
• Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers

  2003cited by this paper
• The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway.

  2002cited by this paper
• Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation.

  2002cited by this paper
• Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.

  2002cited by this paper
• A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin.

  2000cited by this paper
• Mitochondria and calcium: from cell signalling to cell death

  2000cited by this paper
• Studies on the interactions between human serum albumin and trans-indazolium (bisindazole) tetrachlororuthenate(III).

  2000cited by this paper
• Fate of the antimetastatic ruthenium complex ImH [trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice.

  2000cited by this paper
• In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.

  1999cited by this paper
• Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine.

  1999cited by this paper
• Novel cobalt complex inhibitors of mitochondrial calcium uptake.

  1999cited by this paper
• Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex

  1998cited by this paper
• A positive and reversible relationship between adrenergic nerves and alpha-1A adrenoceptors in rat arteries.

  1998cited by this paper
• Oxygen-bridged Dinuclear Ruthenium Amine Complex Specifically Inhibits Ca2+ Uptake into Mitochondria in Vitroand in Situ in Single Cardiac Myocytes*

  1998cited by this paper
• Calcium movements, distribution, and functions in smooth muscle.

  1997cited by this paper
• Efficacy of 5-FU Combined to Na[trans-RuCl4(DMSO)Im], A Novel Selective Antimetastatic Agent, on the Survival Time of Mice With P388 Leukemia, P388/DDP subline and MCa Mammary Carcinoma

  1995cited by this paper
• Action of heparin and ruthenium red on responses of reversibly-permeabilised rat mesenteric arteries.

  1994cited by this paper
• Activation of phospholipase C by alpha 1-adrenergic receptors is mediated by the alpha subunits of Gq family.

  1992cited by this paper
• Br. J. Cancer

  1991cited by this paper
• Functional characterization of the Ca2+-gated Ca2+ release channel of vascular smooth muscle sarcoplasmic reticulum

  1991cited by this paper
• Activation of cerebral guanylate cyclase by nitric oxide.

  1977cited by this paper
• Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine.

  1977cited by this paper
• Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations.

  1977cited by this paper
• CARDIOLOGY

  1921cited by this paper

• Cardiovascular Effects of Ruthenium Complexes: A Potential Therapeutic Tool in Hypertension and Myocardial Injury.

  2025cites this paper
• New Organometallic Ru(II) Compounds with Lonidamine Motif as Antitumor Agents

  2023cites this paper
• Ru(III) Complexes with Lonidamine-Modified Ligands

  2021cites this paper
• Catalytic Radical Reduction in Aqueous Solution by a Ruthenium Hydride Intermediate.

  2016cites this paper